News and Trends 7 Feb 2023AAHI bags $9.9M to develop nasal spray influenza RNA vaccine The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the… February 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023Poolbeg expands POLB 001 into oncology Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule… January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022Poolbeg influenza trial successfully completed Poolbeg Pharma has received initial results having completed its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral… December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 21 Nov 2022Osivax is designing future-proof influenza and Covid vaccines Viruses causing influenza and COVID-19 continually evolve to escape our vaccine protections. The French firm Osivax is developing vaccines that… November 21, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results… November 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule… October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022Pneumagen embarks on phase 2 proof of concept influenza study Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its… August 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Aug 2022Roche announces influenza drug approval and new COVID test Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for… August 15, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners… July 22, 2022 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide… July 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022Additional funding for trial to study drug targeting lung immunity in elderly patients Lung immunity in the elderly will be the subject of a controlled clinical trial after receiving clearance to go ahead… July 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022SINOVAC starts influenza vaccine trial in Chile Sinovac Biotech Ltd., a provider of biopharmaceutical products in China, has initiated a phase III clinical trial for SINOVAC’s inactivated… July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022Osivax gets €10M influenza vaccine grant A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. … June 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email